Pyxis Oncology: HC Wainwright Raises PT to $5, Reiterates Buy Rating

Pyxis Oncology: HC Wainwright Raises PT to $5, Reiterates Buy Rating

Pyxis Oncology, Inc. (Nasdaq: PYXS) has received a positive analyst upgrade from HC Wainwright, which has raised its price target to $5 per share. The investment bank reiterated its "Buy" rating on the biopharmaceutical company [1].

The upgrade comes as Pyxis Oncology's CEO, Lara S. Sullivan, M.D., is scheduled to participate in fireside chats and investor meetings at the RBC Capital Markets Global Healthcare Conference on May 21 and the Jefferies Global Healthcare Conference on June 5 [2]. These events are expected to provide investors with insights into the company's pipeline of advanced antibody-drug conjugates (ADCs) for difficult-to-treat cancers.

Pyxis Oncology's lead candidate, micvotabart pelidotin (MICVO), is currently in Phase 1 clinical studies for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) [2]. Additionally, the company has initiated a Phase 1/2 combination study of MICVO with Merck's KEYTRUDA® (pembrolizumab) for advanced solid tumors [2]. These developments highlight Pyxis Oncology's commitment to addressing tough-to-treat cancers and its potential for strategic partnerships or funding opportunities.

The positive analyst upgrade comes amid recent insider trading activity, with insiders making purchases and institutional investors adding shares to their portfolios [3]. This activity underscores the growing interest in Pyxis Oncology's stock and its potential for growth.

References:
[1] https://www.nasdaq.com/articles/pyxis-oncology-inc-ceo-lara-s-sullivan-participate-upcoming-investor-conferences
[2] https://www.nasdaq.com/articles/pyxis-oncology-inc-ceo-lara-s-sullivan-participate-upcoming-investor-conferences
[3] https://www.nasdaq.com/articles/pyxis-oncology-inc-ceo-lara-s-sullivan-participate-upcoming-investor-conferences